Stock LFVN LIFEVANTAGE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials LifeVantage Corporation

Equities

LFVN

US53222K2050

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
7.53 USD +2.31% Intraday chart for LifeVantage Corporation +11.06% +25.50%
May. 02 Earnings Flash (LFVN) LIFEVANTAGE CORPORATION Reports Q3 Revenue $48.2M, vs. Street Est of $52.2M MT
May. 02 Transcript : LifeVantage Corporation, Q3 2024 Earnings Call, May 02, 2024

Valuation

Fiscal Period: Juni 2021 2023 2024 2025 2026
Capitalization 1 102.9 55.66 95.64 - -
Enterprise Value (EV) 1 102.9 55.66 75.36 71.08 65.33
P/E ratio 8.17 x 21.8 x - - -
Yield - - - - -
Capitalization / Revenue - - 0.47 x 0.46 x 0.44 x
EV / Revenue - - 0.37 x 0.35 x 0.3 x
EV / EBITDA - - 4.25 x 3.68 x 3.03 x
EV / FCF - - 6.68 x 5.85 x 4.74 x
FCF Yield - - 15% 17.1% 21.1%
Price to Book - - - - -
Nbr of stocks (in thousands) 14,005 12,795 12,701 - -
Reference price 2 7.350 4.350 7.530 7.530 7.530
Announcement Date 8/19/21 8/28/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2021 2023 2024 2025 2026
Net sales 1 - - 202.2 205.8 216.2
EBITDA 1 - - 17.73 19.34 21.59
EBIT 1 - - 10.66 11.94 13.84
Operating Margin - - 5.27% 5.8% 6.4%
Earnings before Tax (EBT) - - - - -
Net income 12.89 2.54 - - -
Net margin - - - - -
EPS 0.9000 0.2000 - - -
Free Cash Flow 1 - - 11.28 12.15 13.78
FCF margin - - 5.58% 5.9% 6.37%
FCF Conversion (EBITDA) - - 63.63% 62.84% 63.81%
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 8/19/21 8/28/23 - - -
1USD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: Juni 2022 Q2 2022 Q3 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 52.19 50 - 51.62 48.24 50.95 49.63 52.47 50.22 53.53
EBITDA 1 1.903 3.4 - 3.089 5.077 5.574 4.5 4.004 5.113 5.721
EBIT 1 0.337 - - 1.379 3.386 3.796 2.63 2.204 3.113 3.991
Operating Margin 0.65% - - 2.67% 7.02% 7.45% 5.3% 4.2% 6.2% 7.46%
Earnings before Tax (EBT) - - - - - - - - - -
Net income - - 0.629 - - - - - - -
Net margin - - - - - - - - - -
EPS - - 0.0500 - - - - - - -
Dividend per Share - - - - - - - - - -
Announcement Date 2/1/22 5/3/22 11/9/23 1/30/24 5/2/24 - - - - -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: Juni 2021 2023 2024 2025 2026
Net Debt 1 - - - - -
Net Cash position 1 - - 20.3 24.6 30.3
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 - - 11.3 12.2 13.8
ROE (net income / shareholders' equity) - - 26.9% 32.2% 36.5%
ROA (Net income/ Total Assets) - - 13% 13.8% 14.9%
Assets - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex 1 - - 3 3.25 3.45
Capex / Sales - - 1.48% 1.58% 1.6%
Announcement Date 8/19/21 8/28/23 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
LIFEVANTAGE CORPORATION Stock LifeVantage Corporation
+25.50% 95.64M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.74% 599B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
NOVARTIS AG Stock Novartis AG
+8.44% 205B
ROCHE HOLDING AG Stock Roche Holding AG
-5.97% 203B
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LFVN Stock
  4. Financials LifeVantage Corporation